New and Repurposed Drugs for Pediatric Multidrug-Resistant Tuberculosis. Practice-based Recommendations
MetadataShow full item record
AbstractIt is estimated that 33,000 children develop multidrug-resistant tuberculosis (MDR-TB) each year. In spite of these numbers, children and adolescents have limited access to the new and repurposed MDR-TB drugs. There is also little clinical guidance for the use of these drugs and for the shorter MDR-TB regimen in the pediatric population. This is despite the fact that these drugs and regimens are associated with improved interim outcomes and acceptable safety profiles in adults. This review fills a gap in the pediatric MDR-TB literature by providing practice-based recommendations for the use of the new (delamanid and bedaquiline) and repurposed (linezolid and clofazimine) MDR-TB drugs and the new shorter MDR-TB regimen in children and adolescents.
PublisherAmerican Thoracic Society
DescriptionWe regret that this article is behind a paywall.
- Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany.
- Authors: Wirth D, Dass R, Hettle R
- Issue date: 2017 Mar 8
- Recent controversies about MDR and XDR-TB: Global implementation of the WHO shorter MDR-TB regimen and bedaquiline for all with MDR-TB?
- Authors: Dheda K, Cox H, Esmail A, Wasserman S, Chang KC, Lange C
- Issue date: 2018 Jan
- Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis.
- Authors: Centers for Disease Control and Prevention.
- Issue date: 2013 Oct 25
- New drugs and perspectives for new anti-tuberculosis regimens.
- Authors: Tiberi S, Muñoz-Torrico M, Duarte R, Dalcolmo M, D'Ambrosio L, Migliori GB
- Issue date: 2018 Mar - Apr
- Therapy of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis.
- Authors: Seaworth BJ, Griffith DE
- Issue date: 2017 Mar